Loading...
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
Зохиогч
Sarin, Shiv Kumar
Choudhury, Ashok
Lau, George K
Zheng, Ming-Hua
Ji, Dong
Abd-Elsalam, Sherief
Hwang, Jaeseok
Qi, Xiaolong
Cua, Ian Homer
Suh, Jeong Ill
Park, Jun Gi
Putcharoen, Opass
Kaewdech, Apichat
Piratvisuth, Teerha
Treeprasertsuk, Sombat
Park, Sooyoung
Wejnaruemarn, Salisa
Payawal, Diana A
Ahn, Sang Hoon
Yeo, Chang Dong
Alonzo, Uzziel Romar
Loho, Imelda M
Yokosuka, Osamu
Jafri, Wasim
Tan, Soeksiam
Soo, Lau Ing
Tanwandee, Tawesak
Gani, Rino
Anand, Lovkesh
Esmail, Eslam Saber
Khalaf, Mai
Alam, Shahinul
Lin, Chun-Yu
Chuang, Wan-Long
Soin, A S
Garg, Hitendra K
Kalista, Kemal
Purnomo, Hery Djagat
Dara, Vijay Pal
Rathi, Pravin
Al Mahtab, Mamun
Shukla, Akash
Sharma, Manoj K
Omata, Masao
APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)
Он
2020 оны есдүгээр сар
Төрөл
journal article
Хэвлэгч
Springer Science and Business Media LLC
Journal
Hepatology international
Volume
14
Issue
5
Start Page
690
End Page
700
ISSN
1936-0541
Хураангуй
BACKGROUND AND AIMS: COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis.
METHODS: Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19.
RESULTS: Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1-3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9-38.8), p = 0.002] predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p < 0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC 0.94, HR = 19.2 (95 CI 2.3-163.3), p < 0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis patients.
CONCLUSIONS: SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.
